Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 48, 3440-3444, June 15, 1988]
© 1988 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bravo-Cuellar, A.
Right arrow Articles by Orbach-Arbouys, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bravo-Cuellar, A.
Right arrow Articles by Orbach-Arbouys, S.

Enhanced Activity of Murine Peritoneal Cells after Aclacinomycin Injection: Characteristics of the Enhanced Respiratory Burst

A. Bravo-Cuellar1, F. Homo-Delarche, J. Cabannes and S. Orbach-Arbouys

Institut de Cancérologie et d'Immunogénétique (Université Paris-Sud, Centre National de la Recherche Scientifique UA 04-1163, Association pour la Recherche contre le Cancer and Association Cl.-Bernard), Hôpital Paul-Brousse, 14, av. P. V. Couturier, 94800-Villejuif [A. B-C., J. C., S. O-A.], and Unité 25, Institut National de la Santé et de la Recherche Médicale, Hôpital Necker, 75015-Paris [F. H-D.], France

After the i.p. injection into normal mice, of 4 mg/kg of aclacinomycin (ACM), a dose which prolongs the survival of tumor-bearing mice, the zymosan-elicited chemoluminescence (CL) of the peritoneal cells (PC) is greater than that of control cells. The volume in which the drug is administered plays an important role in the intensity of the response. ACM also stimulated the CL of PC from tumor-bearing mice. It is known that CL can also be elicited by soluble stimuli such as 4ß-phorbol-12-myristate-13{alpha}-acetate or Ca2+ ionophore A 23187, which, however, act in different ways. The response of ACM cells to these stimuli is also greater than in control cells. The enhanced CL of ACM-treated cells can be inhibited by incubating in vitro the zymosan-triggered PC with superoxide dismutase (300 units/ml) and catalase (2750 units/ml), but not with ethanol (20 µM) or potassium cyanide (100 µM). This indicates the participation of O2- and H2O2 in the CL of ACM-treated cells, whereas mitochondrial respiration does not appear to be involved.

Furthermore, the following facts suggest the participation of arachidonic acid metabolism in the control of CL: (a) the in vitro addition of nordihydroguaiaretic acid (7 x 10-6 M) and indomethacin (10-3 M) inhibits the CL, while indomethacin (10-6 M) has the opposite effect; (b) the PC from normal or ACM-treated mice when stimulated with zymosan secrete high amounts of prostaglandin (PG); (c) treated cells secrete the same amounts of PGE2 and 6-keto-PGF1{alpha} but the secretion of PGF2{alpha} and particularly of thromboxane B2 is greater in treated cells than in control cells and indomethacin (10-6 M) strongly inhibits PG secretion in all groups; (d) in vitro addition of PGE2 at a concentration of 10-6 M has an inhibitory effect on the CL emission of control and of treated cells, but it does not have this effect at lower concentrations (10-6 M). These data suggest that the lipoxygenase pathway of arachidonic acid metabolism may be involved in the triggering of CL of ACM-treated cells, as well as that of normal cells, whereas products of the cyclooxygenase pathway may act as feedback inhibitors.

1 To whom requests for reprints should be addressed, at ICIG-Hôpital Paul-Brousse, 14, av. P. V. Couturier, 94800-Villejuif, France.

Received 5/21/87. Revised 1/20/88. Accepted 3/21/88.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1988 by the American Association for Cancer Research.